Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume

OBJECTIVE The objective of this study was to compare fractionation schemes and outcomes of patients with renal cell carcinoma (RCC) treated in institutional prospective spinal stereotactic radiosurgery (SSRS) trials who did not previously undergo radiation treatment at the site of the SSRS. METHODS Patients enrolled in 2 separate institutional prospective protocols and treated with SSRS between 2002 and 2011 were included. A secondary analysis was performed on patients with previously nonirradiated RCC spinal metastases treated with either single-fraction (SF) or multifraction (MF) SSRS. RESULTS SSRS was performed in 47 spinal sites on 43 patients. The median age of the patients was 62 years (range 38–75 years). The most common histological subtype was clear cell (n = 30). Fifteen sites underwent surgery prior to the SSRS, with laminectomy the most common procedure performed (n = 10). All SF SSRS was delivered to a dose of 24 Gy (n = 21) while MF regiments were either 27 Gy in 3 fractions (n = 20) or 30 Gy in 5 fractions (n = 6). The median overall survival duration for the entire cohort was 22.8 months. The median local control (LC) for the entire cohort was 80.6 months with 1-year and 2-year actuarial LC rates of 82% and 68%, respectively. Single-fraction SSRS correlated with improved 1- and 2-year actuarial LC relative to MF SSRS (95% vs 71% and 86% vs 55%, respectively; p = 0.009). On competing risk analysis, SF SSRS showed superior LC to MF SSRS (subhazard ratio [SHR] 6.57, p = 0.014). On multivariate analysis for LC with tumor volume (p = 0.272), number of treated levels (p = 0.819), gross tumor volume (GTV) coverage (p = 0.225), and GTV minimum point dose (p = 0.97) as covariates, MF SSRS remained inferior to SF SSRS (SHR 5.26, p = 0.033) CONCLUSIONS SSRS offers durable LC for spinal metastases from RCC. Single-fraction SSRS is associated with improved LC over MF SSRS for previously nonirradiated RCC spinal metastases.

Download Full-text

Relationship between serum ferritin levels and tumour status in patients with renal cell carcinoma

BJU International ◽

10.1046/j.1464-4096.2001.01323.x ◽

2001 ◽

Vol 88 (9) ◽

pp. 974-977 ◽

Cited By ~ 11

Author(s):

Y. Miyata ◽

S. Koga ◽

M. Nishikido ◽

T. Hayashi ◽

H. Kanetake

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Serum Ferritin ◽

Renal Cell

Download Full-text

Transcriptomic correlates of non-enhancing tumor volume on imaging in clear cell renal cell carcinoma

European Urology Open Science ◽

10.1016/s2666-1683(20)33584-9 ◽

2020 ◽

Vol 19 ◽

pp. e1486-e1487

Author(s):

J. Marcon ◽

C. Duzgol ◽

F. Kuo ◽

K. Weiss ◽

R.G. Di Natale ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Tumor Volume ◽

Clear Cell ◽

Cell Renal Cell Carcinoma

Download Full-text

Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation

Acta Radiologica ◽

10.1177/0284185120909964 ◽

2020 ◽

Vol 61 (12) ◽

pp. 1708-1716

Author(s):

Bruno R Tegel ◽

Steffen Huber ◽

Lynn J Savic ◽

MingDe Lin ◽

Bernhard Gebauer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Tumor Volume ◽

Cox Regression ◽

Imaging Biomarker ◽

Imaging Biomarkers ◽

Secondary Outcome ◽

Tumor Diameter ◽

Renal Metastases

Background The prognosis of patients with renal cell carcinoma (RCC) depends greatly on the presence of extra-renal metastases. Purpose To investigate the value of total tumor volume (TTV) and enhancing tumor volume (ETV) as three-dimensional (3D) quantitative imaging biomarkers for disease aggressiveness in patients with RCC. Material and Methods Retrospective, HIPAA-compliant, IRB-approved study including 37 patients with RCC treated with image-guided thermal ablation during 2007–2015. TNM stage, RENAL Nephrometry Score, largest tumor diameter, TTV, and ETV were assessed on cross-sectional imaging at baseline and correlated with outcome measurements. The primary outcome was time-to-occurrence of extra-renal metastases and the secondary outcome was progression-free survival (PFS). Correlation was assessed using a Cox regression model and differences in outcomes were shown by Kaplan–Meier plots with significance and odds ratios (OR) calculated by Log-rank test/generalized Wilcoxon and continuity-corrected Woolf logit method. Results Patients with a TTV or ETV > 5 cm3 were more likely to develop distant metastases compared to patients with TTV (OR 6.69, 95% confidence interval [CI] 0.33–134.4, P=0.022) or ETV (OR 8.48, 95% CI 0.42–170.1, P=0.016) < 5 cm3. Additionally, PFS was significantly worse in patients with larger ETV ( P = 0.039; median PFS 51.87 months vs. 69.97 months). In contrast, stratification by median value of the established, caliper-based measurements showed no significant correlation with outcome parameters. Conclusion ETV, as surrogate of lesion vascularity, is a sensitive imaging biomarker for occurrence of extra-renal metastatic disease and PFS in patients with RCC.

Download Full-text

The effect of tumor volume on survival in renal cell carcinoma patients

Diagnostic and Interventional Radiology ◽

10.4261/1305-3825.dir.5346-11.1 ◽

2012 ◽

Cited By ~ 1

Author(s):

Mustafa Secil ◽

Nesat Cullu ◽

Guven Aslan ◽

Ugur Mungan ◽

Fatma Uysal ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Tumor Volume

Download Full-text

Durable complete responses and near complete responses to sunitinib in metastatic renal cell carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.15514 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 15514-15514

Author(s):

D. Y. Heng ◽

B. I. Rini ◽

J. Garcia ◽

L. Wood ◽

R. M. Bukowski

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Tumor Volume ◽

Pulmonary Metastases ◽

Cleveland Clinic ◽

Cancer Center ◽

Composite Tumor ◽

Number Of Patients ◽

Metastatic Rcc

15514 Introduction: Sunitinib is a tyrosine kinase inhibitor with activity against VEGFR and PDGFR recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). There is no existing literature that details complete responses (CRs) in patients taking sunitinib for metastatic RCC. Methods: Seventy-four patients with metastatic RCC receiving sunitinib at the Cleveland Clinic Taussig Cancer Center on clinical trials were reviewed to determine the number of patients with RECIST-defined CRs. Additionally, patients who achieved near-CRs defined as a greater than 90% reduction in composite tumor volume or residual disease of less than or equal to 1 cm were reviewed. Results: Two patients (2.7%) achieved a RECIST-defined CR lasting >15 months. The patients who obtained CRs had non-bulky pulmonary metastases, favorable or intermediate MSKCC risk profiles, were treated with sunitinib in the first-line setting and had a significant reduction in composite tumor measurements within the first two cycles. An additional 2 patients achieved near-CRs, including one patient that previously progressed on bevacizumab. These 2 near-CR patients remain progression-free for more than 19 months. Finally, 1 patient achieved sufficient downstaging and reduction of tumor volume such that the remaining lesion could be excised, resulting in a surgical CR. This patient is currently off sunitinib and remains progression-free 4 months after surgery. Conclusion: Sunitinib is capable of producing durable CRs in cytokine-naïve metastatic RCC patients with non-bulky pulmonary metastases. Additionally, near-CRs can be seen despite non-pulmonary metastatic sites and prior VEGF-targeted therapy. No significant financial relationships to disclose.

Download Full-text